Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of…
Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.
Quality of life for colorectal cancer survivors is influenced by physical symptoms, psychological distress, social support, self-efficacy, and demographic factors like age and…
Specific mutations like KRAS, BRAF, and MMR status strongly influence treatment response in colorectal cancer, guiding targeted therapy and immunotherapy decisions.
Yes, home exercise may help reduce fatigue and anxiety in colorectal cancer patients, but the evidence is low certainty and more research is needed.
AI in colorectal cancer treatment faces challenges including data quality and privacy issues, lack of generalizability, interpretability problems, and regulatory validation…
Yes, deep learning can help doctors find breast cancer on tomosynthesis scans, matching or improving radiologist accuracy in some cases.
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for…
Yes, early research shows plasma lipid panels can help detect early-stage breast cancer, with machine learning models achieving high accuracy, but they are not yet standard…
Yes, AI is being researched for breast cancer pathology, including digital pathology, deep learning for imaging, and machine learning for biomarker detection.
After anthracycline failure, trabectedin and eribulin are standard second-line options, while pazopanib is also approved in some regions. Newer agents like repotrectinib are…
A high delta-NLR, which measures the rise in neutrophil-to-lymphocyte ratio during treatment, predicts a worse prognosis for soft tissue sarcoma patients compared to those whose…
Researchers expect to find that second-line drugs like trabectedin, pazopanib, and eribulin offer options after anthracycline failure, but consistent guidelines are still lacking…
Yes, adding regional hyperthermia to chemotherapy may improve survival for extremity soft tissue sarcoma, based on a post-hoc analysis of a randomized trial.
Liver-directed therapy combined with immune checkpoint inhibitors appears most effective; tebentafusp is approved for HLA-A*02:01+ patients; other options include…
Yes, a case report describes a patient with metastatic uveal melanoma who achieved durable disease control after adding SBRT to tebentafusp, with a partial response and 35 months…
Yes, a case report shows tebentafusp plus SBRT controlled metastatic uveal melanoma for over 35 months, but more research is needed to confirm this approach.
Immunoembolization shows lower disease control rates than the FOCUS trial for liver-dominant metastatic uveal melanoma, though tebentafusp combined with radiotherapy may offer…
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Yes, different receptor types in metastatic breast cancer lesions are linked to different survival times, with hormone receptor-positive subtypes generally having longer survival…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.